Industry payments to hospitalist physicians: a 5-year analysis of the Open Payments programme from 2014 to 2018

Intern Med J. 2020 Dec;50(12):1547-1550. doi: 10.1111/imj.15116.

Abstract

We analysed Open Payments programme data (https://openpaymentsdata.cms.gov) on industry-to-physician payments to hospitalists for the years 2014 to 2018. Payments to hospitalists increased by 106.5% from 2014 to 2018 with food and beverage (38.5%) and compensation for services other than consulting (24.3%) being the highest-paid categories. Industry payment to hospitalists was highly skewed with top 10 hospitalists receiving more than 30% of the total payments during the study period. The most common drugs associated with payments were anticoagulant medications (apixaban and rivaroxaban). Industry seems to be spending a significant amount of money to increase awareness of medications among hospitalists. Identification of these trends and potential motives of industry spending is critical to address any potential physician bias.

Keywords: Open Payment programme; disparities; health economics; hospitalist; industry payment.

MeSH terms

  • Conflict of Interest
  • Drug Industry
  • Hospitalists*
  • Humans
  • Industry
  • United States